Everolimus-Associated Thrombotic Microangiopathy Following Renal Transplant: A Case Report.
| Autor: | Leong ZCW; Nephrology, Hospital Pulau Pinang, George Town, MYS., Kong JHL; Nephrology, Hospital Pulau Pinang, George Town, MYS., Khor SY; Pathology, Hospital Seberang Jaya, Permatang Pauh, MYS., Liew YF; Nephrology, Hospital Pulau Pinang, George Town, MYS. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2024 Oct 15; Vol. 16 (10), pp. e71535. Date of Electronic Publication: 2024 Oct 15 (Print Publication: 2024). |
| DOI: | 10.7759/cureus.71535 |
| Abstrakt: | Thrombotic microangiopathy (TMA) is a serious complication that may affect post-renal transplant recipients. De novo TMA has been linked to the use of transplant immunosuppressive agents, including calcineurin inhibitors (CNI) and mammalian target of rapamycin inhibitors (mTORi). We report a case of a 41-year-old female renal transplant recipient who presented with hemolytic anemia, thrombocytopenia, and acute allograft dysfunction. Before her presentation, she was on immunosuppression with oral tacrolimus, oral prednisolone, and oral everolimus. Her renal biopsy showed features of TMA, which led to extensive workup to identify the underlying cause. Eventually, everolimus was recognized as the cause of secondary TMA as her hemolytic parameters and renal allograft function recovered following discontinuation of this drug. This case report highlights the association of everolimus with TMA in a post-renal transplant patient. Early recognition and drug withdrawal can prevent allograft loss. Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work. (Copyright © 2024, Leong et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|